[A21-157] Lusutrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V
Last updated 28.04.2022
Project no.: A21-157
Commission: Commission awarded on 29.12.2021 by the Federal Joint Committee (G-BA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Haematology
Adult patients with severe thrombocytopenia and chronic liver disease who are scheduled to undergo an invasive procedure
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2022-03-01.